ROSIGLITAZONE VS PLACEBO: EFFECT OF CV PERFORMANCE AND MYOCARDIAL TRIGLYCERIDE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this study are to determine if 6 months of treatment with rosiglitazone, a thiazolidmedione medication commonly used in the treatment of hyperglycemia of type 2 diabetes, versus placebo in patients with cardiovascular disease or with an additional cardiovascular risk factor 1) improves integrated cardiovascular performance, assessed by peak oxygen uptake during exercise treadmill testing; 2) effects cardiac structure and function as assess by MRI; and 3) decreases intracellular (ectopic) triglyceride deposition in cardiomyocytes using nuclear magnetic resonance techniques, and how changes in intra-myocardial lipid content relate to changes in cardiac structure and function. This multi-center randomized placebo-controlled double-blinded parallel group study will use the clinical research infrastructure and resources developed in the Donal W. Reynolds Cardiovascular Clinical Research Center at UT Southwestern, and the collaborative participation of the other 3 Reynolds Centers - Stanford, Brigham and Women's Hospital, and Johns Hopkins. Based on the precedent of collaboration established between the UT Southwestern Reynolds Center and the GCRC in the Dallas Heart Study (SPID 0645), GCRC resources will again be utilized for Core Lab and occasional outpatient resources only at UT Southwestern.